Cargando…
Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn(2+) and Oxaliplatin-Associated Pt(2+)
Disappointing results from the POLAR A and M phase III trials involving colorectal cancer patients on chemotherapy with FOLFOX6 in curative (A) and palliative (M) settings have been reported by the principal investigators and the sponsor (PledPharma AB/Egetis Therapeutics AB). FOLFOX6, oxaliplatin i...
Autores principales: | Karlsson, Jan Olof G., Jynge, Per, Ignarro, Louis J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045419/ https://www.ncbi.nlm.nih.gov/pubmed/36978857 http://dx.doi.org/10.3390/antiox12030608 |
Ejemplares similares
-
The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx
por: Karlsson, Jan Olof G., et al.
Publicado: (2021) -
Mangafodipir a Selective Cytoprotectant — with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN)()()
por: Karlsson, Jan Olof G., et al.
Publicado: (2017) -
Classification and Serial Evolution of PLEDs
por: Kim, Ye-Sung, et al.
Publicado: (2006) -
May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?
por: Karlsson, Jan Olof G, et al.
Publicado: (2020) -
Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
por: Karlsson, Jan Olof G., et al.
Publicado: (2019)